Contact Us Facebook

Sarcoma

Sarcomas are a rare, diverse group of cancers that arise from connective and supporting tissues—including muscle, fat, fibrous tissue, blood and lymph vessels, nerves, and bone. They can occur almost anywhere in the body and span many subtypes, most commonly grouped as soft tissue sarcomas and bone sarcomas. Certain sarcomas are site‑specific (e.g., uterine sarcoma) or virus‑driven (e.g., Kaposi sarcoma) and are managed with tailored approaches.

Types of Sarcoma (High‑Level Overview)

Soft Tissue Sarcomas (STS)

a large family (>50 subtypes) that may form in fat, muscle, nerves, vessels, or connective tissue of the arms/legs, trunk, head/neck, or abdomen/retroperitoneum. Common adult subtypes include liposarcoma, leiomyosarcoma, and undifferentiated pleomorphic sarcoma.

Bone Sarcomas

e.g., osteosarcoma, which typically arises in the long bones (often near the knee) and occurs more often in children, teens, and young adults, but can occur at any age.

Rhabdomyosarcoma (RMS)

the most common soft tissue sarcoma in children/adolescents; arises from early skeletal muscle cells and can start in the head/neck, genitourinary tract, or extremities (arms/legs). Adults can develop RMS as well.

Kaposi Sarcoma (KS)

a vascular sarcoma driven by HHV‑8 (KSHV) infection; lesions often appear on skin or mucosa, and KS can involve lymph nodes, lungs, or GI tract. It is more common with immune suppression (e.g., HIV).

Uterine Sarcoma

a rare sarcoma that starts in the muscle (leiomyosarcoma) or supporting tissues of the uterus (e.g., endometrial stromal sarcoma, undifferentiated uterine sarcoma, adenosarcoma). It is distinct from the far more common endometrial (uterine lining) carcinoma.

Signs & Symptoms

  • Soft tissue sarcoma: often a painless, enlarging lump deep or superficial to the skin; symptoms vary by location (e.g., swelling, pain, or functional limitation).
  • Bone sarcoma (osteosarcoma): bone/joint pain and/or swelling (often near knee/shoulder); sometimes a palpable mass or limp.
  • Rhabdomyosarcoma: depends on site—head/neck (nasal congestion/vision changes), GU tract (urinary symptoms or bleeding), or extremities (growing mass).
  • Kaposi sarcoma: purple/red/brown lesions on skin or oral mucosa; internal involvement (lung/GI) can cause breathing problems or GI bleeding.
  • Uterine sarcoma: abnormal vaginal bleeding is common; pelvic pain, mass, or pressure can occur.

Risk Factors

  • Inherited syndromes (e.g., Li‑Fraumeni, NF1) increase risk for certain soft tissue sarcomas; prior radiation and specific chemical exposures are additional risk factors in select subtypes.
  • Kaposi sarcoma requires infection with HHV‑8; risk is higher with immune suppression (e.g., HIV/AIDS, post‑transplant immunosuppression).
  • Uterine sarcoma risk is higher after pelvic radiation and can be associated with tamoxifen use; evaluation is warranted for any unexpected uterine bleeding.

Diagnosis & Staging

Evaluation typically involves: 

(often MRI for limb/trunk STS; CT for chest/abdomen/pelvis; site‑specific imaging for uterine or visceral tumors) helps define extent and resectability. Chest imaging is commonly performed because many sarcomas metastasize to the lungs.

(planned along a potential surgical path) is the standard for soft tissue and bone sarcomas; pathology with immunohistochemistry and, when needed, molecular testing confirms histologic subtype and grade.

typically used to confirm Kaposi sarcoma; additional tests evaluate for internal involvement (e.g., endoscopy, bronchoscopy, CT imaging) when indicated.

and surgical/pathological staging required by Uterine sarcoma; it is distinct from endometrial carcinoma in work‑up and management.

Treatment Options

Care is individualized based on sarcoma subtype, size, grade, and location, as well as stage and overall health—coordinated by a multidisciplinary team (surgery, medical oncology, radiation oncology, pathology, radiology, and—for uterine sarcoma—gynecologic oncology).

Soft Tissue Sarcoma (Adults)

  • Surgery with a goal of complete, margin‑negative resection is the cornerstone for localized disease; radiation therapy may be used pre‑ or post‑operatively to reduce local recurrence risk depending on tumor size, depth, and anatomic constraints.
  • Systemic therapy (chemotherapy, targeted therapy, immunotherapy) is considered in select subtypes or advanced/metastatic disease; choices are guided by histology and clinical factors. Clinical trials are encouraged given the rarity and heterogeneity of STS.

Osteosarcoma (Bone)

  • Combination therapy with surgery (limb‑sparing whenever feasible) plus multi‑agent chemotherapy is standard; outcomes depend on stage and response to therapy. (Radiation is rarely used.)
  • Overall, ~60–70% of people with osteosarcoma can be cured, especially when disease is localized at diagnosis.
Invasive to muscles

Rhabdomyosarcoma

Multimodality therapy (chemotherapy plus surgery and/or radiation) is typical; cure rates are high in localized pediatric RMS, but high‑risk or relapsed disease needs specialized approaches and trials.

Kaposi Sarcoma

Management depends on type (e.g., HIV‑associated vs. classic/iatrogenic), extent, and symptoms. Strategies may include local therapies (e.g., surgery, topical agents, intralesional chemo), radiation, systemic chemotherapy, or immunotherapy. For HIV‑associated KS, antiretroviral therapy is essential and may control disease.

Uterine Sarcoma

Surgery (hysterectomy ± salpingo‑oophorectomy) is the mainstay for early stage disease; depending on histology and stage, radiation, chemotherapy, hormone therapy, and increasingly targeted or immunotherapy may be considered for advanced disease. Because uterine sarcomas are rare, clinical trials are encouraged whenever available.

Prognosis

  • Prognosis varies widely by subtype, stage, grade, and site. For soft tissue sarcomas, survival and patterns of spread depend on histology and anatomic location (e.g., extremity vs. retroperitoneal).
  • In osteosarcoma, survival is highest for localized disease and lower for metastatic or relapsed disease.
  • Many sarcomas—especially when localized—are potentially curable with modern, coordinated care. Clinical trials continue to drive improvements and expand options.

Follow-Up & Survivorship 

After treatment, we create a personalized surveillance plan that may include:

  • Periodic imaging of the primary site and chest (common metastatic site for many sarcomas) based on subtype and stage.
  • Rehabilitation, pain/symptom management, and psychosocial support to optimize function and quality of life.
  • Genetic counseling when hereditary risk is suspected (especially with personal/family patterns or early‑onset disease).

Why Choose Illinois CancerCare

  • Multidisciplinary sarcoma expertise—coordinating surgery, radiation, systemic therapy, imaging, pathology, genetics, and supportive care—close to home.
  • Clinical trials access and referral pathways for rare sarcoma subtypes Current Clinical Trials – Illinois CancerCare

Sources & Patient Friendly References

All information was taken from the NCI (National Cancer Institute) and ACS (American Cancer Society).